SSRIs and SNRIs aim to increase monoamine availability, and they also support neuroplasticity by increasing brain-derived neurotrophic factor (BDNF) and exhibit modest anti-inflammatory effects, suggesting a connection between inflammation and MDD (207, 208). This evidence concerns the gene BDNF and major depressive disorder.